ACM
RVNC

ADAR1 Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

ADAR1 Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-182,166
Closed -$945K – 322
2024
Q3 		$945K Buy
+182,166
New +$905K 0.15% 81

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

ADAR1 Capital Management's RVNC Position: Q4 2024 in Review

ADAR1 Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 182,166 shares — an estimated $945K sold.

ADAR1 Capital Management first reported a position in RVNC in Q3 2024 and held it in 1 quarter. The position peaked at $945K in Q3 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • ADAR1 Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 182,166 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $945K.
  • ADAR1 Capital Management first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 1 quarter.
  • ADAR1 Capital Management's Revance Therapeutics, Inc. position peaked at $945K in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.